Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non Operating Income: 2017-2025

Historic Non Operating Income for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to $12.5 million.

  • Crinetics Pharmaceuticals' Non Operating Income rose 13.91% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 63.30%. This contributed to the annual value of $40.9 million for FY2024, which is 208.17% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Non Operating Income is $12.5 million, which was down 7.27% from $13.5 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Non Operating Income ranged from a high of $14.6 million in Q1 2025 and a low of -$68,000 during Q3 2021.
  • Its 3-year average for Non Operating Income is $8.6 million, with a median of $8.7 million in 2024.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Non Operating Income tumbled by 151.91% in 2021 and then skyrocketed by 4,447.46% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Non Operating Income (Quarterly) stood at -$59,000 in 2021, then surged by 4,447.46% to $2.6 million in 2022, then spiked by 163.63% to $6.8 million in 2023, then spiked by 109.26% to $14.2 million in 2024, then rose by 13.91% to $12.5 million in 2025.
  • Its Non Operating Income was $12.5 million in Q3 2025, compared to $13.5 million in Q2 2025 and $14.6 million in Q1 2025.